On June 1, GenScript Biotech fell 5.19% in regular trading, trading at HKD 12.98/share, with trading volume of HKD 116 million.

The decline represents a continuation of profit-taking following the ASCO annual meeting catalyst. GenScript's associate company Legend Biotech presented multiple research results at the ASCO conference, including Phase 1 clinical data for LB2102, a DLL3-targeting CAR-T therapy for relapsed or refractory small cell lung cancer, alongside new CARVYKTI data. This news had driven the stock up over 5% on May 27, but subsequent sessions have seen sustained selling pressure as the positive catalyst was fully digested.

Adding to downside pressure, Hong Kong Stock Connect channels recorded consecutive large-scale net outflows in recent sessions, raising concerns that institutional investors leveraged the ASCO rally to reduce positions. At the sector level, the Life Sciences Tools and Services space broadly weakened, with Insilico Medicine down 6.88%, XtalPi down 2.79%, and WuXi XDC down 2.19%, amplifying the sector-wide drag on GenScript.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)